NAB815

NAB815 is a specific inhibitor of the Stx2a (Kd = 0.01 μM) /TLR4 interaction. NAB815 inhibits the neutrophil/Stx2a interaction (IC50 = 0.057 μg/mL) . NAB815 inhibits the formation of Stx2-containing extracellular vesicles (EVs) produced by leukocytes and platelets and reduces their toxic effects in cellular (Vero cells) and animal models (CD-1 mice) . NAB815 reduces bacterial loads in the kidneys, urine, and bladders of Escherichia coli-infected mice. NAB815 is useful in the study of hemolytic uremic syndrome (HUS) [1][2].

1969250-99-4

12352209

Bacterial; Toll-like Receptor (TLR)

Anti-infection; Immunology/Inflammation

COVID-19-immunoregulation

Infection

O=C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@](C(NCC[C@@H](C(N[C@H](C(N1)=O)CCN)=O)NC([C@@H]([C@@H](O)C)NC([C@H]([C@H](O)C)NC([C@H](CCN)NC(CCCCCCC)=O)=O)=O)=O)=O)([H])[C@H](O)C)=O)CCN)=O)CC)=O)CC(C)C)[C@H]1CC2=CC=CC=C2

C55H94N14O14

1175.42

[1]Varrone E, et al. An antibiotic derivative as a new potential tool in the prevention of hemolytic uremic syndrome. iScience. 2025 Jul 7;28 (8) :113076.|[2]Vaara M, et al. Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis. J Antimicrob Chemother. 2018 Feb 1;73 (2) :452-455.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11232/

Peptides

No Development Reported